Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premedication dexamethasone to prevent ILD with trastuzumab deruxtecan in metastatic breast cancer
2025-521798-15-00Phase 3Authorised
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexamethasone in breast cancer (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Cumulative incidence of ILD > Grade 1 at 12 months. Planned start Aug 2026; status: authorised.
02
Drugs
dexamethasone
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521798-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521798-15-00.